arrow
Back
D

David F. McDermott

dana-farber cancer institute

109H-index
1.1KPaper Count
8.9WCitation Count
Published Papers 160
Publication Date
The clinical landscape of HIF2α inhibitors in oncology
err2026-04-28
err0
PREAI
errEddy Saad; Marc Machaalani; David F. McDermott; Toni K. Choueiri
errShare
errSave
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers
err2025-12-13
err0
errOAAI
errRana R. McKay MD; Sumanta Pal MD; Wanling Xie MS; David Aggen MD, PhD; Laurence Albiges MD, PhD; Andrea Apolo MD; Michael B. Atkins MD; Rick Bangs MBA, PMP; Kathryn E. Beckermann MD, PhD; Joaquim Bellmunt MD, PhD; Stephanie A. Berg DO; Mehmet A. Bilen MD; David Braun MD, PhD; Maria I. Carlo MD; Jason Efstathiou MD, DPhil; Matthew Galsky MD; Petros Grivas MD, PhD; Shilpa Gupta MD; Naomi Haas MD; A. Ari Hakimi MD; Hans Hammers MD, PhD; Daniel Y. C. Heng MSC; Michelle Hirsch MD, PhD; Gopakumar Iyer MD; Eric Jonasch MD; Vadim S. Koshkin MD; Oleksandr Kryvenko MD; Bryan Lewis JD; Roger Li MD; Surena Matin MD; Benjamin Maughan MD, PharmD; David F. McDermott MD; Bradley McGregor MD; Joshua Meeks MD, PhD; Matthew Milowsky MD; Robert Motzer MD; Andrea Necchi MD; Dan Petrylak MD; Sima Porten MD, MPH; Thomas Powles MBBS, MRCP, MD; Brian Rini MD; Brian Shuch MD; Arlene Siefker-Radtke MD; Guru Sonpavde MD; S. Srikala Sridhar MD; Cristina Suarez MD, PhD; Chad Tang MD; Abhishek Tripathi MD; Michiel S. Van Der Heijden MD, PhD; Martin Voss MD; Wenxin Xu MD; Tian Zhang MD; Jonathan Rosenberg MD; Toni K. Choueiri MD
errShare
errSave
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
err2025-11-01
err0
PREAI
errWirth, Lena Vanessa; Hugaboom, Miya B.; Street, Kelly; Ruthen, Neil; Jegede, Opeyemi; Schindler, Nicholas; Shah, Valisha; Zaemes, Jacob; El Ahmar, Nourhan; Matar, Sayed; Savla, Varunika; Choueiri, Toni; Denize, Thomas; West, Destiny; Mcdermott, David F.; Plimack, Elizabeth R.; Sosman, Jeffrey; Haas, Naomi; Hurwitz, Michael E.; Hammers, Hans; Stein, Mark; Alter, Robert; Bilen, Mehmet; Signoretti, Sabina; Atkins, Michael B.; Wu, Catherine J.; Braun, David
errShare
errSave
CD163+Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial
err2025-10-01
err0
errOAAI
errSimsek, Berkay; Paul, Morgan A.; Xie, Wanling; El Ahmar, Nourhan; Matar, Sayed; Laimon, Yasmin Nabil; RobertiDe Oliveira, Gabriel; Mohanna, Razan; Delcea, Andrew; Choueri, Toni; Braun, David; Sun, Maxine; Haas, Naomi B.; Hammers, Hans J.; Bilen, Mehmet; Stein, Mark N.; Sosman, Jeffrey A.; Freeman, Gordon J.; Wu, Catherine; Mcdermott, David; Atkins, Michael B.; Signoretti, Sabina
errShare
errSave
Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)
err2025-10-01
err0
errOAAI
errChen, Yu-Wei; Nazari, Shayan; Elliott, Andrew; Kulkami, Ninad; Smith, Norm; Nawfal, Rashad; Barata, Pedro C.; Bagrodia, Aditya; Rose, Brent; McDermott, David; Signoretti, Sabina; Machaalani, Marc; Shiva, Shankar; Hofman, Michael; Agarwal, Neeraj; Pal, Sumanta; Choueri, Toni; Mckay, Rana
errShare
errSave
Immunotherapy response correlates in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes
err2025-10-01
err0
errOAAI
errEl Hajj Chehade, Razane; Semaan, Karl; Zhang, Ze; Phillips, Noa; Canniff, John; Savignano, Hunter; Nawfal, Rashad; Eid, Marc; Grisham, Lexi; Prather, Rebecca; Beckermann, Katy; Vaishampayan, Ulka; Haas, Naomi; Hammers, Hans; McDermott, David; Wood, Lauren; Solley, Travis; Rini, Brian; Jonasch, Eric; Choueiri, Toni K.; Freedman, Matthew L.; Haake, Scott M.; Baca, Sylvan C.; Berchuck, Jacob E.
errShare
errSave
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes
err2025-02-01
err0
PREAI
errXu, W.; Birch, G.; Meliki, A.; Moritz, V.; Bharadwaj, M.; Schindler, N. R.; Labaki, C.; Saliby, R. M.; Dinh, K.; Horst, J. T.; Sun, M.; Kashima, S.; Hugaboom, M.; Dighe, A.; Machaalani, M.; Lee, G. -s. m.; Hurwitz, M.; Mcgregor, B. A.; Hirsch, M. S.; Shukla, S. A.; Mcdermott, D. F.; Signoretti, S.; Romee, R.; Choueiri, T. K.; Braun, D. A.
errShare
errSave
Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
err2024-11-01
err0
errOAAI
errTannir, N. M.; Albiges, L.; Mcdermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Barthelemy, P.; Plimack, E. R.; Portat, C.; George, S.; Donskov, F.; Atkins, M. B.; Gurney, H.; Kollmannsberger, C. K.; Grimm, M. -o.; Barrios, C.; Tomita, Y.; Castellano, D.; Gruenwald, V.; Rini, B. I.; Jiang, R.; Desilva, H.; Fedorov, V.; Lee, C. -w.; Motzer, R. J.
errShare
errSave
Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
err2024-09-01
err1
PREAI
errZugman, M.; McDermott, D. F.; Escudier, B.; Hutson, T. E.; Porta, C. G.; Verzoni, E.; Atkins, M. B.; Rini, B. I.; Pal, S. K.
errShare
errSave
A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7
err2024-09-01
err0
PREAI
errCheng, H.; Rivera, I. I. Rodriguez; McDermott, D. F.; Spira, A. I.; Ged, Y.; Liu, J.; Ji, Y.; Rausch, M.; Hashambhoy-Ramsay, Y.; Kis-Toth, K.; Gandhi, L.; Naing, A.
errShare
errSave
Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
err2024-09-01
err0
PREAI
errVaishampayan, U. N.; Saavedra, A. J. Zurita; Beckermann, K.; Chain, A.; Vickery, D.; Zhang, Y.; Perini, R.; McDermott, D. F.
errShare
errSave
Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
err2024-09-01
err0
PREAI
errMcGregor, B. A.; Paul, M.; Xie, W.; Xu, W.; Bilen, M. A.; Braun, D. A.; Berg, S.; Zhang, T.; McKay, R. R.; McDermott, D. F.; Hammers, H.; Choueiri, T. K.
errShare
errSave
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
err2024-06-01
err3
PREAI
errCarril-Ajuria, Lucia; Lavaud, Pernelle; Dalban, Cecile; Negrier, Sylvie; Gravis, Gwenaelle; Motzer, Robert J.; Chevreau, Christine; Tannir, Nizar M.; Oudard, Stephane; McDermott, David F.; Laguerre, Brigitte; Hammers, Hans J.; Barthelemy, Philippe; Plimack, Elizabeth R.; Borchiellini, Delphine; Gross-Goupil, Marine; Jiang, Ruiyun; Lee, Chung-Wei; de Silva, Heshani; Rini, Brian I.; Escudier, Bernard; Albiges, Laurence
errShare
errSave
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
err2024-04-18
err40
PREAI
errChoueiri, T. K.; Tomczak, P.; Park, S. H.; Venugopal, B.; Ferguson, T.; Symeonides, S. N.; Hajek, J.; Chang, Y-H; Lee, J-L; Sarwar, N.; Haas, N. B.; Gurney, H.; Sawrycki, P.; Mahave, M.; Gross-Goupil, M.; Zhang, T.; Burke, J. M.; Doshi, G.; Melichar, B.; Kopyltsov, E.; Alva, A.; Oudard, S.; Topart, D.; Hammers, H.; Kitamura, H.; McDermott, D. F.; Silva, A.; Winquist, E.; Cornell, J.; Elfiky, A.; Burgents, J. E.; Perini, R. F.; Powles, T.
errShare
errSave
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
err2024-04-11
err2
errOAAI
errAtkins, Michael B.; Jegede, Opeyemi A.; Haas, Naomi B.; Mcdermott, David F.; Bilen, Mehmet A.; Stein, Mark; Sosman, Jeffrey; Alter, Robert; Plimack, Elizabeth R.; Ornstein, Moshe C.; Hurwitz, Michael; Peace, David J.; Einstein, David; Catalano, Paul J.; Hammers, Hans; Regan, Meredith M.
errShare
errSave
Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
err2024-04-05
err1
PREAI
errIzar, Benjamin; Zamarin, Dmitriy; Spigel, David R.; Hoimes, Christopher J.; McDermott, David F.; Sehgal, Kartik; Najjar, Yana G.; Schoenfeld, Adam J.; Garon, Edward B.; Sullivan, Ryan J.; Henick, Brian S.; Leal, Ticiana A.; Hurwitz, Michael E.; McKay, Rana R.; Busby, Natalie; Mehta-Damani, Anita; Azrilevich, Alex; Tran, Tony; Rizvi, Naiyer; Oft, Martin; Spira, Alexander I.
errShare
errSave
High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma
err2024-03-22
err0
PREAI
errVemula, Sai Vikram; Xu, Wenxin; Wang, Yu; Liu, Xiaowen; de Somocurcio, Jorge Ruiz; McDermott, David; Li, Jun; Bhatt, Rupal; Lee, Chung-Wei; Simsek, Burcin; Gupta, Saurabh; Motzer, Robert
errShare
errSave
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
err2024-03-01
err12
errOAAI
errBrahmer, Julie R.; Long, Georgina, V; Hamid, Omid; Garon, Edward B.; Herbst, Roy S.; Andre, Thierry; Armand, Philippe; Bajorin, Dean; Bellmunt, Joaquim; Burtness, Barbara; Choueiri, Toni K.; Cohen, Ezra E. W.; Diaz Jr, Luis A.; Shitara, Kohei; Kulkarni, Girish; McDermott, David; Shah, Manish; Tabernero, Josep; Vogel, Arndt; Zinzani, Pier Luigi; Jafari, Niusha; Birdu, Steven; Snyderu, Ellen; Gause, Christine; Braccou, Oswaldo L.; Pietanza, M. Catherine; Gruberu, Todd; Ribas, Antoni
errShare
errSave
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
err2024-01-01
err7
PREAI
errJonasch, Eric; Bauer, Todd M.; Papadopoulos, Kyriakos P.; Plimack, Elizabeth R.; Merchan, Jaime R.; Mcdermott, David F.; Michaelson, M. Dror; Appleman, Leonard J.; Roy, Ananya; Perini, Rodolfo F.; Liu, Yanfang; Choueiri, Toni K.
errShare
errSave